Home Today’s Briefing Deep Dives In Play Trending For You Discover My Stack Saved Off Radar Search

Loading today’s stories

Today

AI-assisted reporting, grounded in a per-article claim ledger. Perspective Coverage and Reality Strip separate source viewpoints from evidence, adoption, hype, incentives, and confidence.

Today

Front Page
Today’s Briefing
Newsletters
Trending
For You
Discover
My Stack
Saved
Off Radar
Search

Sections

Security
Build
Invest
Product
Leadership
Science

Company

About
Mission
How this is made
Evidence Index
The desks
The sources we read
Corrections
Press and brand
The daily edition

Trending now

ClickFix-Style Social Engineering
Context Engineering
Semiconductor Partnerships
Custom AI Accelerators
Infostealer Malware
CGRP-targeted therapeutics
Medication safety in pregnancy
Migraine prevention
CTE in Football
Donor-Cohort Selection Bias

How this is made

Today For You My Stack Off Radar Search

Rimegepant (Nurtec) — other — Clarity Today

other

Rimegepant (Nurtec)

CGRP-blocking drug approved in 2021 for episodic migraine prevention, recommended only for patients who fail better-evidenced options.

Known aliases

Nurtec

Relationships

No evidence-backed relationships are recorded.

Current clusters

science2 distinct publishers

Migraine prevention guidelines elevate CGRP drugs after a 14-year gap

After 14 years without a revision, US neurologists and headache specialists have folded CGRP-targeted drugs into the front rank of migraine prevention. That changes the first conversation in the clinic and the coverage fight behind it.

Publishers:sciencenews.org · statnews.com

Reality

Evidence71
Adoption44
Hype gap+17
Incentives61

Confidence68